The success of targeted therapies in cancer treatment has been impeded by various
mechanisms of resistance. Besides the acquisition of resistance-conferring genetic …

Persistent cancer cells are the discrete and usually undetected cells that survive cancer drug
treatment and constitute a major cause of treatment failure. These cells are characterized by …

Drug resistance in cancer is often linked to changes in tumor cell state or lineage, but the
molecular mechanisms driving this plasticity remain unclear. Using murine organoid and …

In castration-resistant prostate cancer (CRPC), the loss of androgen receptor (AR)
dependence leads to clinically aggressive tumors with few therapeutic options. We used …

Prostate cancer adeno-to-neuroendocrine lineage transition has emerged as a mechanism
of targeted therapeutic resistance. Identifying the direct molecular drivers and develo** …

Tumor expression of prostate-specific membrane antigen (PSMA) is lost in 15–20% of men
with castration-resistant prostate cancer (CRPC), yet the underlying mechanisms remain …

Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent
through several comprehensive profiling efforts, but little is known about the impact of this …

Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …

Metastatic prostate cancer (mPC) comprises a spectrum of diverse phenotypes. However,
the extent of inter-and intra-tumor heterogeneity is not established. Here we use digital …

Lineage plasticity, the ability of cells to transition from one committed developmental
pathway to another, has been proposed as a source of intratumoural heterogeneity and of …